Courtney et al. reported that PT2385, a HIF-2α antagonist, has a favorable safety profile and is active in patients with previously heavily pretreated clear-cell renal cell carcinoma (ccRCC), validating direct HIF-2α antagonism for the treatment of patients with ccRCC [135]. This evidence concerns the gene EPAS1 and clear cell renal carcinoma.